| Diabetes is the most common metabolic disease. Type 2 diabetes is a variable combination
of insulin resistance and disorder in insulin secretion, leading to disorder of lipids and plasma
lipoproteins. The most common pattern of dyslipidemia in diabetic is high triglyceride (TG)
and low high‑density lipoprotein cholesterol (HDL‑C). This study was conducted to find a
more effective drug to increase HDL‑C. In this study, 80 patients (26 males and 54 females)
with type 2 diabetes received fenofibrate in cross‑sectional way for 2 months, and they
did not take antilipid drugs for 2 month. Then, they underwent atorvastatin for 2 months
and HDL‑C was measured before and after taking drugs. Patients did not change their diet
during this study. Effect of atorvastatin and fenofibrate on HDL‑C levels in patients with
type 2 diabetes was evaluated. The mean HDL‑C and total cholesterol (TC) before and after
taking drugs were 36.5 mg/dL and 174.56 mg/dL, respectively. After atorvastatin, the mean
HDL‑C and TC were 43.30 and 150.144 mg/dL, respectively, and after fenofibrate, 43.40
were mg/dL and 146.36 mg/dL, respectively. Atorvastatin caused increase in HDL‑C by
18.44% and reduction in TC by 13.82% and fenofibrate increase in HDL‑C by18.62% and
reduction in TC by 16.05%. No difference was seen between atorvastatin and fenofibrate
in terms of effect on the HDL‑C excess (P = 0.449). In addition, no difference was seen
between atorvastatin and fenofibrate in terms of effect on TC reduction (P = 0.992). In
conclusion various factors are involved in increasing the HDL, such as race, sex, nutrition,
physical activity and, of course, medications. The effect of medications is also different on
races and genetics. The value of increase in HDL-C after Fenofibrate and Atorvastatin was
associated with gender so that it caused more increase of HDL-C in females. |